Lupin gets USFDA approval for Sevelamer Hydrochloride Tablets

17 Jun 2021 Evaluate

Lupin has received approval for its Sevelamer Hydrochloride Tablets, 400 mg and 800 mg from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation. The product will be manufactured at Lupin’s facility in Nagpur, India.

Sevelamer Hydrochloride Tablets are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2112.75 23.10 (1.11%)
17-Dec-2025 11:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1774.75
Dr. Reddys Lab 1275.35
Cipla 1493.60
Zydus Lifesciences 917.20
Lupin 2112.75
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×